Investment in China

Merck isn't the first pharmaceutical company to invest in research in China, but it sure is spending a lot more, says ScienceInsider's Hao Xin. The company says it plans to spend about $1.5 billion on R&D in China over the next five years, starting with a staff of 260 in Beijing. Merck already has a commercial headquarters in Shanghai and has built manufacturing facilities in other parts of China, Xin says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.